Condition: Thyroid Neoplasms · Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
The study aims to observe and investigate the efficacy and safety of Anlotinib capsules in patients with locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma in the real world, and to summarize the treatment experience in a broad population.
This description comes directly from the study's public registry record.
Ming Gao, PhD · + 86 18622221110 · gaoming68@aliyun.com
Yansong Lin, PhD · +86 13671116837 · linys@pumch.cn
Always discuss trial participation with your own doctor first.
| Peking Union Medical College Hospital, Chinese Academy of Medical Sciences | Beijing, Beijing Municipality, China | Recruiting |
| Tianjin People's Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
| Tianjin Cancer Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05994365